United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 19.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 263,349 shares of the company's stock after purchasing an additional 42,308 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned approximately 0.06% of Zoetis worth $33,135,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. RFG Advisory LLC raised its position in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock valued at $215,000 after buying an additional 80 shares during the period. YANKCOM Partnership grew its stake in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company's stock valued at $302,000 after acquiring an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. grew its stake in Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company's stock valued at $537,000 after acquiring an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its holdings in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company's stock valued at $240,000 after purchasing an additional 86 shares during the period. Finally, Financial Engines Advisors L.L.C. lifted its position in shares of Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on ZTS. Argus reaffirmed a "hold" rating on shares of Zoetis in a research report on Wednesday. Wall Street Zen lowered shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Weiss Ratings lowered shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $190.00 to $130.00 and set an "overweight" rating on the stock in a research note on Friday, May 8th. Finally, BTIG Research reiterated a "buy" rating and issued a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $133.92.
Check Out Our Latest Stock Analysis on Zoetis
Zoetis Trading Down 1.4%
NYSE:ZTS opened at $78.36 on Friday. The stock's 50 day moving average price is $105.08 and its 200 day moving average price is $117.31. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The company has a market capitalization of $32.85 billion, a P/E ratio of 12.99, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.
Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the company posted $1.48 EPS. The company's quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.
Zoetis Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis's dividend payout ratio is presently 35.16%.
Key Zoetis News
Here are the key news stories impacting Zoetis this week:
Insiders Place Their Bets
In related news, Director Frank A. Damelio bought 6,650 shares of the firm's stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company's stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of the firm's stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company's stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is currently owned by company insiders.
About Zoetis
(
Free Report)
Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
